Boards must prepare for when things begin returning to normal again. How a company bounces back from this devastation could determine its survival. 

In the fallout of COVID-19, technology has become the one sector that has uniquely benefited from the isolated workforce and the need for novel medicine. But the reliance on tech, medical technology and biotechnology in this uncertain time has provided opportunities for non-tech firms to unite with tech and medical leaders as well.

The COVID-19 crisis left organizations in a tough spot. How boards reacted in the face of this pressure may leave them liable, according to recent situations with similar outbreaks and illnesses.

In the U.S., where health insurance through an employer is the primary way to receive care, many patients may abstain from going to the doctor due to costs. This has the potential to further the spread of the virus and has put insurers in the spotlight.

Chipotle Mexican Grill informed shareholders that it would reduce the size of the board by three directors when it announced its founder was stepping away from the company. In what situations does a reduced board make sense? It depends on the complexity of the business — but oftentimes, slimmer works better.